NeoTract Announces Sponsorship of Fifth Annual Drive for Men’s Health
WAYNE, Pa.--(BUSINESS WIRE)-- NeoTract, a wholly owned subsidiary of Teleflex Incorporated (NYSE:TFX) focused on addressing unmet needs in the field of urology, today announced its sponsorship of the fifth annual “Drive for Men’s Health” event. Funds raised by this campaign will be donated to Florida Polytechnic University and Cochrane Urology, a division of Cochrane Collaboration, to support the latest research, education, and awareness-generating efforts in the mission to improve men’s health.
The event, now in its fifth consecutive year, is an initiative launched by Dr. Jamin Brahmbhatt and Dr. Sijo Parekattil, co-directors of The PUR Clinic (Personalized Urology & Robotics) at South Lake Hospital in Clermont, Florida. The Drive combines cars, technology, and educational events to encourage men to talk about their health. As in years past, Drs. Parekattil and Brahmbhatt will embark on a cross-country journey in a new BMW i8 June 1st beginning in Orlando, Florida, with stops in New York, Philadelphia, Columbus, Chicago, and Houston featuring speakers, events and educational activities to raise awareness about men’s health. The drive will cover a distance of 4000 miles and will conclude on June 9th in Clermont, Florida.
“We’re proud to once again support the Drive for Men’s Health,” said Dave Amerson, President of the Interventional Urology business unit. “Drs. Brahmbhatt and Parekattil’s passion for helping men to live their best and healthiest lives have impacted many men as well as their partners and families. There are conditions, such as with benign prostatic hyperplasia (BPH), which men tolerate as an inevitable part of the aging process. Education is the key factor to getting men in to see their doctors, receiving preventative care, and maintaining optimal health.”
Recent NeoTract sponsored surveys of more than 1,000 men and 1,000 women over the age of 50 in the U.S. aimed to measure the impact of BPH on couples, as well as ascertain the reasons why men may not be seeking treatment for their symptoms. More than one-third of male respondents were not aware these symptoms were signs of a treatable condition, rather than just a result of aging.
The Drive for Men’s Health reaches 300 million people across the United States. The Drive will include a fashion show, educational seminars on nutrition, and cooking demonstrations from noteworthy chefs.
“The fact is that men go to the doctor less frequently than women, and are less forthcoming about their health when they do visit,” said Dr. Sijo Parekattil, co-founder of the Drive for Men’s Health. “Our aim is to increase awareness of men’s health issues and to encourage men to make their health a priority; part of that means educating them about safe and simple procedures available today. NeoTract has been an invaluable partner in this goal. The UroLift System offers a minimally invasive treatment option to a very common condition, and has the potential to dramatically increase quality of life for men suffering from symptoms of an enlarged prostate.”
Nearly 40 million men in the United States are affected by BPH. Not to be confused with prostate cancer, BPH occurs when the prostate gland that surrounds the male urethra becomes enlarged with advancing age and begins to obstruct the urinary system. Symptoms of BPH often include interrupted sleep and urinary problems, and can cause loss of productivity, depression and decreased quality of life.
About the UroLift System
The FDA-cleared UroLift System is a proven, minimally invasive technology for treating lower urinary tract symptoms due to benign prostatic hyperplasia (BPH). The UroLift permanent implants, delivered during a minimally invasive transurethral outpatient procedure, relieve prostate obstruction and open the urethra directly without cutting, heating, or removing prostate tissue. Clinical data from a pivotal 206-patient randomized controlled study showed that patients with enlarged prostate receiving UroLift implants reported rapid and durable symptomatic and urinary flow rate improvement without compromising sexual function. Patients also experienced a significant improvement in quality of life. More than 50,000 men worldwide have been treated with the UroLift System. Most common adverse events reported include hematuria, dysuria, micturition urgency, pelvic pain, and urge incontinence. Most symptoms were mild to moderate in severity and resolved within two to four weeks after the procedure. The UroLift System is available in the U.S., Europe, Australia, Canada, Mexico and South Korea. Learn more at www.UroLift.com.
About NeoTract | Teleflex Interventional Urology
A wholly owned subsidiary of Teleflex Incorporated, the NeoTract Interventional Urology Business Unit is dedicated to developing innovative, minimally invasive and clinically effective devices that address unmet needs in the field of urology. Our initial focus is on improving the standard of care for patients with BPH using the UroLift System, a minimally invasive permanent implant system that treats symptoms while preserving normal sexual function. Learn more at www.NeoTract.com.
About Teleflex Incorporated
Teleflex is a global provider of medical technologies designed to improve the health and quality of people’s lives. We apply purpose driven innovation – a relentless pursuit of identifying unmet clinical needs – to benefit patients and healthcare providers. Our portfolio is diverse, with solutions in the fields of vascular and interventional access, surgical, anesthesia, cardiac care, urology, emergency medicine and respiratory care. Teleflex employees worldwide are united in the understanding that what we do every day makes a difference. For more information, please visit www.teleflex.com.
Teleflex is the home of Arrow®, Deknatel®, Hudson RCI®, LMA®, Pilling®, Rusch®, Weck® and the UroLift® System – trusted brands united by a common sense of purpose.
For Teleflex Incorporated
Jake Elguicze, 610-948-2836
Treasurer and Vice President, Investor Relations
Nicole Osmer, 650-454-0505